Given the shortage of Genzyme’s Cerezyme treatment for Gaucher disease, European regulators decided to grant an accelerated review for Shire’s velaglucerase.
Venture-rich Clovis Oncology has struck its first in-license cancer deal, paying Norwegian firm Clavis $15 M upfront and up to $365 M in milestones for rights in the Americas and Europe to a reformulated version of pancreatic cancer drug gemcitabine.
DDMAC gets aggressive on downplaying risk info, sends three letters in three weeks.
Merck wins second fosamax trial after questioning qualifications of expert witness.
